Backs FY26 operating expense view $450M-$470M. The company said, “The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB, to be between $635 million and $660 million.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target
- BioCryst Posts Q1 2026 Results, Maintains Growth Outlook
- BioCryst Licenses European Rights to HAE Drug Navenibart
- BioCryst enters navenibart license agreement with Neopharmed Gentili
- BioCryst Pharmaceuticals (BCRX) Q1 Earnings Cheat Sheet